Development of novel vaccine vectors: Chimpanzee adenoviral vectors

58Citations
Citations of this article
98Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Adenoviral vector has been employed as one of the most efficient means against infectious diseases and cancer. It can be genetically modified and armed with foreign antigens to elicit specific antibody responses and T cell responses in hosts as well as engineered to induce apoptosis in cancer cells. The chimpanzee adenovirus-based vector is one kind of novel vaccine carriers whose unique features and non-reactivity to pre-existing human adenovirus neutralizing antibodies makes it an outstanding candidate for vaccine research and development. Here, we review the different strategies for constructing chimpanzee adenoviral vectors and their applications in recent clinical trials and also discuss the oncolytic virotherapy and immunotherapy based on chimpanzee adenoviral vectors.

Cite

CITATION STYLE

APA

Guo, J., Mondal, M., & Zhou, D. (2018, July 3). Development of novel vaccine vectors: Chimpanzee adenoviral vectors. Human Vaccines and Immunotherapeutics. Taylor and Francis Inc. https://doi.org/10.1080/21645515.2017.1419108

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free